Author/Authors :
Li، نويسنده , , Liang and Li، نويسنده , , Min and Sun، نويسنده , , Canlan and Francisco، نويسنده , , Liton and Chakraborty، نويسنده , , Sujata and Sabado، نويسنده , , Melanie and McDonald، نويسنده , , Tinisha and Gyorffy، نويسنده , , Janelle and Chang، نويسنده , , Karen and Wang، نويسنده , , Shirong and Fan، نويسنده , , Wenhong and Li، نويسنده , , Jiangning and Zhao، نويسنده , , Lue Ping and Radich، نويسنده , , Jerald and Forman، نويسنده , , Stephen and Bhatia، نويسنده , , Smita and Bhatia، نويسنده , , Ravi، نويسنده ,
Abstract :
Summary
y-related myelodysplasia or acute myeloid leukemia (t-MDS/AML) is a major complication of cancer treatment. We compared gene expression in CD34+ cells from patients who developed t-MDS/AML after autologous hematopoietic cell transplantation (aHCT) for lymphoma with controls who did not develop t-MDS/AML. We observed altered gene expression related to mitochondrial function, metabolism, and hematopoietic regulation in pre-aHCT samples from patients who subsequently developed t-MDS/AML. Progression to overt t-MDS/AML was associated with additional alterations in cell-cycle regulatory genes. An optimal 38-gene PBSC classifier accurately distinguished patients who did or did not develop t-MDS/AML in an independent group of patients. We conclude that genetic programs associated with t-MDS/AML are perturbed long before disease onset, and accurately identify patients at risk for this complication.
